132 related articles for article (PubMed ID: 11432538)
1. Application of a gamma model of absorption to oral cyclosporin.
Debord J; Risco E; Harel M; Le Meur Y; Büchler M; Lachâtre G; Le Guellec C; Marquet P
Clin Pharmacokinet; 2001; 40(5):375-82. PubMed ID: 11432538
[TBL] [Abstract][Full Text] [Related]
2. Population pharmacokinetic model to predict steady-state exposure to once-daily cyclosporin microemulsion in renal transplant recipients.
Schädeli F; Marti HP; Frey FJ; Uehlinger DE
Clin Pharmacokinet; 2002; 41(1):59-69. PubMed ID: 11825097
[TBL] [Abstract][Full Text] [Related]
3. Maximum a posteriori Bayesian estimation of oral cyclosporin pharmacokinetics in patients with stable renal transplants.
Leger F; Debord J; Le Meur Y; Rousseau A; Büchler M; Lachâtre G; Paintaud G; Marquet P
Clin Pharmacokinet; 2002; 41(1):71-80. PubMed ID: 11825098
[TBL] [Abstract][Full Text] [Related]
4. Cyclosporin pharmacokinetics in paediatric transplant recipients.
Cooney GF; Habucky K; Hoppu K
Clin Pharmacokinet; 1997 Jun; 32(6):481-95. PubMed ID: 9195117
[TBL] [Abstract][Full Text] [Related]
5. Population pharmacokinetic modeling of oral cyclosporin using NONMEM: comparison of absorption pharmacokinetic models and design of a Bayesian estimator.
Rousseau A; Léger F; Le Meur Y; Saint-Marcoux F; Paintaud G; Buchler M; Marquet P
Ther Drug Monit; 2004 Feb; 26(1):23-30. PubMed ID: 14749545
[TBL] [Abstract][Full Text] [Related]
6. Bayesian estimation of cyclosporin exposure for routine therapeutic drug monitoring in kidney transplant patients.
Bourgoin H; Paintaud G; Büchler M; Lebranchu Y; Autret-Leca E; Mentré F; Le Guellec C
Br J Clin Pharmacol; 2005 Jan; 59(1):18-27. PubMed ID: 15606436
[TBL] [Abstract][Full Text] [Related]
7. A comparison of the pharmacokinetics of tacrolimus and microemulsified cyclosporin in paediatric renal transplant recipients.
Renton KW; Crocker JF; McLellan H; Acott PD
Eur J Clin Pharmacol; 2004 Aug; 60(6):421-6. PubMed ID: 15232662
[TBL] [Abstract][Full Text] [Related]
8. A double absorption-phase model adequately describes mycophenolic acid plasma profiles in de novo renal transplant recipients given oral mycophenolate mofetil.
Prémaud A; Debord J; Rousseau A; Le Meur Y; Toupance O; Lebranchu Y; Hoizey G; Le Guellec C; Marquet P
Clin Pharmacokinet; 2005; 44(8):837-47. PubMed ID: 16029068
[TBL] [Abstract][Full Text] [Related]
9. Population pharmacokinetics and bayesian estimator of cyclosporine in pediatric renal transplant patients.
Irtan S; Saint-Marcoux F; Rousseau A; Zhang D; Leroy V; Marquet P; Jacqz-Aigrain E
Ther Drug Monit; 2007 Feb; 29(1):96-102. PubMed ID: 17304156
[TBL] [Abstract][Full Text] [Related]
10. Impact of absorption profiling on efficacy and safety of cyclosporin therapy in transplant recipients.
Belitsky P; Dunn S; Johnston A; Levy G
Clin Pharmacokinet; 2000 Aug; 39(2):117-25. PubMed ID: 10976658
[TBL] [Abstract][Full Text] [Related]
11. [Cyclosporin pharmacokinetic modeling in renal transplant patients].
Porta Oltra B; Pérez Ruixo JJ; Jiménez Torres NV; Pallardó Mateu L
Farm Hosp; 2004; 28(1):5-19. PubMed ID: 15012174
[TBL] [Abstract][Full Text] [Related]
12. Microemulsion technology in the reformulation of cyclosporine: the reason behind the pharmacokinetic properties of Neoral.
Ritschel WA
Clin Transplant; 1996 Aug; 10(4):364-73. PubMed ID: 8884110
[TBL] [Abstract][Full Text] [Related]
13. Limited sampling strategies using Bayesian estimation or multilinear regression for cyclosporin AUC(0-12) monitoring in cardiac transplant recipients over the first year post-transplantation.
Monchaud C; Rousseau A; Leger F; David OJ; Debord J; Dantoine T; Marquet P
Eur J Clin Pharmacol; 2003 Apr; 58(12):813-20. PubMed ID: 12698308
[TBL] [Abstract][Full Text] [Related]
14. Bayesian forecasting of oral cyclosporin pharmacokinetics in stable lung transplant recipients with and without cystic fibrosis.
Rousseau A; Monchaud C; Debord J; Vervier I; Estenne M; Thiry P; Marquet P
Ther Drug Monit; 2003 Feb; 25(1):28-35. PubMed ID: 12548141
[TBL] [Abstract][Full Text] [Related]
15. Modelling ciclosporin double-peak absorption profiles in the early post-transplantation period.
Rousseau A; Marquet P
Clin Pharmacokinet; 2004; 43(14):1055-7. PubMed ID: 15530133
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic advantages of two-hour post-dose cyclosporin a level for the therapeutic drug monitoring in stable Chinese kidney transplant recipients.
Leung CB; Szeto CC; Ho CS; Law WK; Lam CW; Li PK
Nephron Clin Pract; 2005; 99(3):c68-72. PubMed ID: 15650318
[TBL] [Abstract][Full Text] [Related]
17. Differences in clearance of mycophenolic acid among renal transplant recipients, hematopoietic stem cell transplant recipients, and patients with autoimmune disease.
de Winter BC; Mathot RA; Sombogaard F; Neumann I; van Hest RM; Doorduijn JK; van Gelder T
Ther Drug Monit; 2010 Oct; 32(5):606-14. PubMed ID: 20720518
[TBL] [Abstract][Full Text] [Related]
18. Benefits of cyclosporine absorption profiling in nephrotic syndrome: preprandial once-daily administration of cyclosporine microemulsion improves slow absorption and can standardize the absorption profile.
Takeda A; Horike K; Onoda H; Ohtsuka Y; Yoshida A; Uchida K; Morozumi K
Nephrology (Carlton); 2007 Apr; 12(2):197-204. PubMed ID: 17371346
[TBL] [Abstract][Full Text] [Related]
19. Effect of gastrointestinal inflammation and age on the pharmacokinetics of oral microemulsion cyclosporin A in the first month after bone marrow transplantation.
Schultz KR; Nevill TJ; Balshaw RF; Toze CL; Corr T; Currie CJ; Strong DK; Keown PA
Bone Marrow Transplant; 2000 Sep; 26(5):545-51. PubMed ID: 11019845
[TBL] [Abstract][Full Text] [Related]
20. How to convert from traditional cyclosporine to the microemulsion formulation in stable renal transplant patients?
Gaspari F; Perico N; Pisoni R; Anedda MF; Signorini O; Caruso R; Gotti E; Remuzzi G
Clin Transplant; 1998 Oct; 12(5):379-90. PubMed ID: 9787945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
